A federal jury in California found that Kite Pharma - now part of Gilead Sciences - violated a patent from Memorial Sloan Kettering Cancer Center and licensed to BMS' Juno Therapeutics in developing the CAR-T therapy Yescarta, approved in 2017.
The new fund, announced Thursday by Arie Belldegrun's Vida Ventures, brings the total amount of money raised to approximately $1 billion.
A new report from Relatient, A Data-Driven Guide to Patient Access Succes, highlights how focusing on data accuracy and relevance can enhance the performance of healthcare practices.
The company, led by a Gilead Sciences veteran, plans to use the platform to find drugs that go after "undruggable" targets.
The company presented end-of-Phase I data from the trial, on KTE-X19, at the ASCO meeting in Chicago Saturday.
The company, part of Gilead Sciences since 2017, had placed an early emphasis on ensuring manufacturing capacity could meet demand - a key consideration in cell and gene therapy.
Along with Boston Scientific's Watchman in the technology category, Novartis and Gilead's Kite shared the biotechnology award for CAR-T therapy, while Celgene/Agios's Idhifa won the pharmaceutical prize.
Choosing the right software translates directly into better client management, operational efficiency and growth for your spa franchise. Discover which tool is best for your business.
A manufacturing error during a clinical trial of Kymriah, now marketed by Novartis, is less likely today, but could be an issue as CAR-Ts move into earlier therapy lines.
The deal will bring the CAR-T therapy to China's burgeoning market, but it faces competition from Gilead's Yescarta - manufactured under a JV with Fosun - and also homegrown products.
The filing comes one week after the company, founded earlier this year with a $300 million Series A round by two former Kite executives, raised $120 million in a private financing.
Keeping manufacturing close to home allows for greater flexibility, lower long-term costs and building up native manufacturing capability, panelists said at the B. Riley Health Conference Tuesday.
Every wellness clinic is only as successful as the capabilities of its software. Here's where you can find the top-rated practice management solutions for med spas.
Led by two Kite founders, the company launched with $300 million in VC funding in April and plans a registration trial of Servier's UCART19 and clinical development of its own allogeneic CAR-Ts next year.
Non-binding vote by MEDCAC supports use of PROs in CAR-T clinical trials, drawing opposition from industry and oncology groups.
CMS could run trials of CAR-Ts in lymphoma if unsure of their similarity on benefit to patients and ancillary service costs, Dr. Peter Bach writes.
Assuming all goes well, potential prostate cancer drug candidate could enter clinic by end of next year, Norbert Bischofberger says.
The clinical trial of the CAR-T - a potential competitor to bluebird bio's - will start enrolling patients later this year.